Navigation Links
Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent
Date:5/20/2008

CALGARY, May 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,374,752 entitled "Reovirus for the Treatment of Cellular Proliferative Disorders." The claims cover pharmaceutical compositions which comprise various recombinant reoviruses.

"This patent provides the Company with additional patent protection for reovirus compositions in the United States," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals a
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Global Stem Cells Group subsidiary Adimarket ... biologic products for the regeneration and repair of human organs ... Cells Group’s ambitious expansion plans in Latin America, a commitment ... regenerative medicine and stem cell therapies. , Bioquark ... have the ability to alter the regulatory state of human ...
(Date:6/2/2015)... June 02, 2015 Research and Markets( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:6/2/2015)...   Hospira, Inc. (NYSE: HSP ), ... partner, Celltrion – a global biopharmaceutical company – has received ... in Brazil – for Remsima ... in Brazil . The medication will ... biosimilar infliximab in 26 European countries and in ...
(Date:6/2/2015)... 2, 2015   Intrexon Corporation (NYSE: ... announced today the appointment of Olivier R. ... Sector.  Mr. Jarry will lead the expansion of ... applications for consumer markets.  Mr. ... experience in leading global life sciences and consumer ...
Breaking Biology Technology:Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 2Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 3Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5Intrexon Announces New Sector Leader 2Intrexon Announces New Sector Leader 3
... a development that holds much promise for the future ... of solar energy to produce clean and renewable liquid ... Lawrence Berkeley National Laboratory (Berkeley Lab) have reported a ... of the semiconductor cadmium-selenide was increased 100,000 times. ...
... , , VANCOUVER, British ... company, dedicated to the commercializing of a unique drug ... medical devices, announced today that it will present full ... catheters at the 2009 Interscience Conference on Antimicrobial Agents ...
... , GENEVA, Sept. 11 Friendly LRL ... previously-announced tender offer to acquire all of the outstanding shares ... STHK) ("Startech"), effective immediately. FLH,s offer was scheduled to ... September 30, 2009. All shares previously tendered pursuant to ...
Cached Biology Technology:Gold solution for enhancing nanocrystal electrical conductance 2Gold solution for enhancing nanocrystal electrical conductance 3Enox Biopharma Will Present Its Unique Self-Sterilizing Urinary Catheter at the 49th Annual ICAAC Meeting. 2Enox Biopharma Will Present Its Unique Self-Sterilizing Urinary Catheter at the 49th Annual ICAAC Meeting. 3Friendly LRL Holdings Terminates Offer To Acquire Startech Environmental Corporation 2Friendly LRL Holdings Terminates Offer To Acquire Startech Environmental Corporation 3
(Date:5/22/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... its promotional pricing and making the Wocket generally available for ... , Head of Marketing said, "We,ve extended the opportunity to ... of May. To get your wocket at this special price, ... store on June 1, you,ll receive a unique code that ...
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2
... -- FirstMark, the diagnostic division of GenWay ... company will be exhibiting at the inaugural Atlanta ... of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory ... provide a new, needs-based and convenient forum for ...
... Center of NYU School of Medicine will hold its ... honor three outstanding leaders in biomedical research. The Dart/NYU ... in the development of pharmaceuticals and honors those scientists ... care provided at the patient,s bedside. Recipients of this ...
... VIEW, CA (April 6, 2012) Using its ... company, has found five significant genetic associations for hypothyroidism ... conducted to date. The details of the study are ... . "With nearly 90 percent of our 125,000 ...
Cached Biology News:FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update 2NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 2NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 3NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 4NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 523andMe identifies 5 significant genetic associations for hypothyroidism 2
... The new Class II safety cabinets Heraeus HERAsafe ... and user-orientated design. ,The new frameless slanted ... work area. The new front window design makes ... The large work aperture with a height of ...
... The Jouan MSC series of ... comfortable working conditions and certification to ... automatic regulation ensures that the cabinets ... working conditions. Natural lighting, low noise ...
... a custom synthesis service for synthetic ... molecules are: Composed of 18-20 ... overhang at the 3-terminus PAGE ... and ready-to-use. Simply order your ...
... shaker stands both present the ... height, and help protect user ... tubular steel, these heavy-duty accessories ... weight and minimize the vibration ...
Biology Products: